@article{a04ff8be21cf4234bb04be2d0269803b,
title = "Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling",
abstract = "The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.",
keywords = "Autologous stem cell transplantation, Endpoint, Immune profiling, Minimal residual disease, Multiple myeloma",
author = "Holstein, {Sarah A.} and Ye, {J. Christine} and Alan Howard and Manisha Bhutani and Nicole Gormley and Theresa Hahn and Jens Hillengass and Amrita Krishnan and Landgren, {C. Ola} and Munshi, {Nikhil C.} and Stefania Oliva and Owen, {Roger G.} and Pasquini, {Marcelo C.} and Noemi Puig and Niels Weinhold and Katja Weisel and McCarthy, {Philip L.}",
note = "Funding Information: Financial disclosure: Support for the Blood and Marrow Transplant Clinical Trials Network was provided by Grant U10 HL069294 from the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute. Support for the PRIMeR ancillary study was provided by NHLBI Grant R01 HL107213 . Support for the IP studies performed at Levine Cancer Institute was provided by Conquer Cancer Foundation ASCO Young Investigator Award, the Carolinas Myeloma Research Fund, and the Leukemia Lymphoma Society. Funding Information: Conflict of interest statement: S.A.H. has served on advisory boards for Celgene, Amgen, Adaptive Biotechnology, and Takeda and has served as a consultant for Celgene. M.B. has received institutional clinical trial funding from MedImmune, Millennium, Prothena, and Janssen and has received speaking fees from Amgen, Bristol Myers Squibb and Takeda Oncology. T.H. has received research funding from Celgene. J.H. has received honoraria and travel support from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda and research funding from Celgene and Sanofi. A.K. has served as a consultant for Celgene and Janssen; has served on speakers bureaus for Celgene, Takeda, Onyx, and Janssen; has received research funding from Janssen; and has stock in Celgene. C.O.L. has received institutional research funding from Amgen, Celgene, Janssen, and Takeda. N.C.M. has served as a consultant for Biotest, Celgene, Janssen, Pfizer, Merck, Oncopep, and Takeda and is a part owner and shareholder of Oncopep. S.O. has received honoraria from Amgen, Celgene, Janssen, and Takeda. R.G.O. has received honoraria from Celgene, Janssen, and Takeda; has served on advisory boards for Celgene and Janssen; and has received travel and meeting support from Janssen. M.P. has received honoraria from Amgen and Celgene. N.P. has received honoraria and/or research funding from Amgen, Celgene, Janssen, and Takeda. K.W. has received institutional research funding from Amgen, Celgene, and Sanofi. P.L.M. has received honoraria from Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda, and Binding Site; has received research funding from Celgene; and has served on advisory committees/review panels/boards for Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda, Binding Site, and Karyopharm. The other authors have no conflicts of interest to report. ",
year = "2019",
month = mar,
doi = "10.1016/j.bbmt.2018.11.001",
language = "English (US)",
volume = "25",
pages = "e89--e97",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",
}